Assay C-peptide, IGF-1, IGFBP-3, adiponectin, and HMW adiponectin in serum samples taken most proximal to diagnosis among 699 PLCO prostate cancer in men.

Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI) plans to procure on a sole source basis with Sir Mortimer B. Davis Jewish General Hospital 3755 Cote-Ste-Catherine Road, Montreal, Quebec, H3T 1E2 Canada to assay C-peptide, IGF-1, IGFBP-3, adiponectin, and HMW adiponectin in serum samples taken most proximal to diagnosis among 699 PLCO prostate cancer in men. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541380 and the business size standard is $12M. Period of performance is for six months from time of award. It has been determined that there is no opportunity to acquire green products or services under this contract. NCI intends to replicate and extend the findings related to energetic biomarkers and the association with prostate cancer mortality in the PLCO Cancer Screening Trial. The contractor will assay the concentration of five energetic analytes including C-peptide, IGF-1, IGFBP-3, adiponectin, and HMW-adiponectin in serum taken most proximal to prostate cancer diagnosis in 699 men in PLCO (including 115 fatal cases and 6 QC individuals). The levels of concentration of each analyte will be evaluated separately and in combination with respect to risk of prostate cancer mortality, while accounting for D'amico score, treatment status, and additional comorbidities. After NCI has validated the associations between prostate cancer mortality and each of these 5 analytes, NCI will pool our data with the other cohorts to validate the prediction model. NCI will replicate the association reported by two other prospective cohorts between prostate cancer mortality and C-peptide, IGF-1, IGFBP-3, and adiponectin. The concentration of these analytes was measured by Sir Mortimer B. Davis Jewish General Hospital for both of these cohorts. Once NCI's independent analysis of these analytes is completed, NCI intends to pool the data with the other cohorts to validate the prediction models. Contracting with the same lab that was used by the other cohorts is necessary to reduce any unwanted variability in the measurements, and is critical for scientific comparability. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 17, 2012. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed +1 (555) 000-0000 or emailed to Erin Breedlove, Contract Specialist at contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120152-EB on all correspondence.